We met with Gerard Criner, of Temple University, at ERS 2019 in Madrid, to discuss his presentation on identification of patients with chronic obstructive pulmonary disease who benefit from benralizumab.
Questions
1. What is the mechanism of action of benralizumab?
2. Could you tell us a little about the aims and design of the GALATHEA and TERRANOVA clinical studies?
3. What were the findings of these studies?
4. Could these findings be explained by any patient factors?
5. What will be the next step in identifying patients with chronic obstructive pulmonary disease who benefit from benralizumab?
Speaker disclosures: Gerard Criner has received funding from Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, Eolo Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Olympus, Philips Respironics, PulmonX, Respivant Sciences, Verona Pharma.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
